Skip to main content

Table 5 Crude and adjusted Cox regression models stratified by age regarding the association of sex steroid treatment with death due to COVID-19

From: Estrogen-modulating treatment among mid-life women and COVID-19 morbidity and mortality: a multiregister nationwide matched cohort study in Sweden

Death due to COVID-19

  

Exposed

Unexposed

 

Exposure

Age (years)

n total

n events (%)

n total

n events (%)

Crude HR (95% CI)

Adjusted HR (95% CI)a

Local estrogens alone

53–62

2577

0 (0.00)

12,885

0 (0.00)

NE

NE

63–72

2976

5 (0.17)

14,880

6 (0.04)

4.17 (1.27–13.65)

4.33 (1.31–14.30)

 > 73

4428

45 (1.02)

22,124

108 (0.49)

2.08 (1.47–2.95)

1.87 (1.32–2.65)

Systemic estrogens without progestogens

53–62

2715

0 (0.00)

13,576

0 (0.00)

NE

NE

63–72

308

0 (0.00)

1540

0 (0.00)

NE

NE

 > 73

166

5 (3.01)

830

4 (0.48)

6.25 (1.68–23.27)

4.73 (1.22–18.32)

Systemic estrogens and progestogens

53–62

7508

0 (0.00)

37,535

1 (0.00)

NE

NE

63–72

654

0 (0.00)

3270

1 (0.03)

NE

NE

 > 73

190

0 (0.00)

950

2 (0.21)

NE

NE

Progestogens alone

53–62

8803

0 (0.00)

44,016

1 (0.00)

NE

NE

63–72

316

0 (0.00)

1580

0 (0.00)

NE

NE

 > 73

204

2 (0.98)

1020

6 (0.59)

1.67 (0.34–8.26)

2.03 (0.40–10.43)

Tibolone alone

53–62

699

0 (0.00)

3495

0 (0.00)

NE

NE

63–72

175

0 (0.00)

875

0 (0.00)

NE

NE

 > 73

49

0 (0.00)

245

0 (0.00)

NE

NE

  1. Abbreviations: HR Hazard ratio, CI Confidence intervals, ICU Intensive care unit, NE Not estimated
  2. aModels adjusted for occupation, family type, education, obesity, alcohol dependence syndrome, and Charlson Comorbidity Index